keyword
MENU ▼
Read by QxMD icon Read
search

Dimethyl fumarate

keyword
https://www.readbyqxmd.com/read/28814828/comparison-of-efficacy-and-safety-of-oral-agents-for-the-treatment-of-relapsing-remitting-multiple-sclerosis
#1
REVIEW
Cristina Guarnera, Placido Bramanti, Emanuela Mazzon
In the therapeutic scenario of disease-modifying therapies for relapsing-remitting multiple sclerosis, the introduction of oral agents, starting in 2010 with fingolimod, has been a huge step forward in therapeutic options due to the easier administration route. Three oral drugs fingolimod, teriflunomide, and dimethyl fumarate, which are clinically approved for the treatment of relapsing-remitting multiple sclerosis, are reviewed in this work. Results of Phase III clinical trials and their extension studies showed that the three oral agents significantly reduced the annualized relapse rate - a superior efficacy compared to placebo...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28783872/evaluation-of-potential-drug-drug-interaction-between-delayed-release-dimethyl-fumarate-and-a-commonly-used-oral-contraceptive-norgestimate-ethinyl-estradiol-in-healthy-women
#2
Bing Zhu, Ivan Nestorov, Guolin Zhao, Venkata Meka, Mark Leahy, Jeanelle Kam, Sarah I Sheikh
Delayed-release dimethyl fumarate (DMF) is an oral therapy for relapsing multiple sclerosis with anti-inflammatory and neuroprotective properties. This 2-period crossover study was conducted to evaluate the potential for drug-drug interaction between DMF (240 mg twice daily) and a combined oral contraceptive (OC; norgestimate 250 μg, ethinyl estradiol 35 μg). Forty-six healthy women were enrolled; 32 completed the study. After the lead-in period (OC alone), 41 eligible participants were randomized 1:1 to sequence 1 (OC and DMF coadministration in period 1; OC alone in period 2) or sequence 2 (regimens reversed)...
August 7, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28770420/efficacy-and-tolerability-of-delayed-release-dimethyl-fumarate-in-black-hispanic-and-asian-patients-with-relapsing-remitting-multiple-sclerosis-post-hoc-integrated-analysis-of-define-and-confirm
#3
Robert J Fox, Ralf Gold, J Theodore Phillips, Macaulay Okwuokenye, Annie Zhang, Jing L Marantz
INTRODUCTION: Clinical course and treatment response may vary according to race/ethnicity in multiple sclerosis (MS) patients. Delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) demonstrated significant efficacy and a favorable benefit-risk profile in relapsing-remitting MS (RRMS) patients in the 2-year phase III DEFINE/CONFIRM studies. METHODS: In this post hoc analysis of integrated data from DEFINE/CONFIRM, we assessed clinical efficacy and safety/tolerability in black, Hispanic, and Asian patients treated with DMF 240 mg twice daily (approved dosage) or placebo...
August 2, 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28751099/efficacy-and-safety-of-delayed-release-dimethyl-fumarate-for-relapsing-remitting-multiple-sclerosis-in-prior-interferon-users-an-integrated-analysis-of-define-and-confirm
#4
Óscar Fernández, Gavin Giovannoni, Robert J Fox, Ralf Gold, J Theodore Phillips, James Potts, Macaulay Okwuokenye, Jing L Marantz
PURPOSE: In Phase III studies (DEFINE [Determination of the Efficacy and Safety of Oral Fumarate in Relapsing-Remitting MS]/CONFIRM [Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis]), delayed-release dimethyl fumarate (DMF) demonstrated significant efficacy and a favorable benefit-risk profile in patients with relapsing-remitting multiple sclerosis (RRMS). Post hoc analyses of integrated data from DEFINE/CONFIRM were conducted to evaluate the effect of DMF in patients previously treated with interferon (IFN) beta...
July 24, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28747150/reply-to-letter-to-the-editor-dimethyl-fumarate-for-patients-with-neuromyelitis-optica-spectrum-disorder-by-pitarokoili-and-gold
#5
Jun-Ichi Kira
No abstract text is available yet for this article.
July 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28747147/dimethyl-fumarate-for-patients-with-neuromyelitis-optica-spectrum-disorder
#6
Kalliopi Pitarokoili, Ralf Gold
No abstract text is available yet for this article.
July 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28740339/treatment-with-dimethyl-fumarate-ameliorates-liver-ischemia-reperfusion-injury
#7
Chie Takasu, Nosratola D Vaziri, Shiri Li, Lourdes Robles, Kelly Vo, Mizuki Takasu, Christine Pham, Seyed H Farzaneh, Mitsuo Shimada, Michael J Stamos, Hirohito Ichii
AIM: To investigate the hypothesis that treatment with dimethyl fumarate (DMF) may ameliorate liver ischemia/reperfusion injury (I/RI). METHODS: Rats were divided into 3 groups: sham, control (CTL), and DMF. DMF (25 mg/kg, twice/d) was orally administered for 2 d before the procedure. The CTL and DMF rats were subjected to ischemia for 1 h and reperfusion for 2 h. The serum alanine aminotransferase (ALT) and malondialdehyde (MDA) levels, adenosine triphosphate (ATP), NO × metabolites, anti-oxidant enzyme expression level, anti-inflammatory effect, and anti-apoptotic effect were determined...
July 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28737986/real-world-adherence-and-persistence-to-oral-disease-modifying-therapies-in-multiple-sclerosis-patients-over-1-year
#8
Kristen M Johnson, Huanxue Zhou, Feng Lin, John J Ko, Vivian Herrera
BACKGROUND: Disease-modifying therapies (DMTs) are indicated to reduce relapse rates and slow disease progression for relapsing-remitting multiple sclerosis (MS) patients when taken as prescribed. Nonadherence or non-persistence in the real-world setting can lead to greater risk for negative clinical outcomes. Although previous research has demonstrated greater adherence and persistence to oral DMTs compared with injectable DMTs, comparisons among oral DMTs are lacking. OBJECTIVE: To compare adherence, persistence, and time to discontinuation among MS patients newly prescribed the oral DMTs fingolimod, dimethyl fumarate, or teriflunomide...
August 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28733990/dimethyl-fumarate-modulates-neutrophil-extracellular-trap-formation-in-a-glutathione-and-superoxide-dependent-manner
#9
J H O Hoffmann, K Schaekel, D Hartl, A H Enk, E N Hadaschik
BACKGROUND: Neutrophil (polymorphonuclear) granulocytes (PMN) were shown to contribute to the pathogenesis of psoriasis by releasing IL-17 and LL-37/ DNA complexes via neutrophil extracellular traps (NET), webs of chromatin strands decorated with antimicrobial peptides, in psoriatic skin. Fumaderm(®) , a fumaric acid ester (FAE) formulation consisting of different FAE salts has been successfully used to treat psoriasis for decades. Most recently, FAE treatment was reported to inhibit NET formation in murine epidermolysis bullosa acquisita...
July 22, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28709939/transdermal-delivery-of-dimethyl-fumarate-for-alzheimer-s-disease-effect-of-penetration-enhancers
#10
Dina Ameen, Bozena Michniak-Kohn
Dimethyl fumarate (DMF) is an orally administered drug with neuroprotective and immunomodulatory activities. It has potential uses in the treatment of neurodegenerative diseases such as Alzheimer's disease (AD). The objective of this study was to investigate the feasibility of transdermal delivery of DMF by studying the effect of different penetration enhancers on the skin permeation of DMF. The permeation of saturated DMF solutions was investigated in propylene glycol (PG) with varying concentrations of each of the following enhancers: Polysorbate 80 (T80), N-methyl pyrrolidone (NMP), laurocapram (Azone(®)) (Az), Transcutol P (Tc), Terpineol (Terp), and cineole (Cin) using vertical Franz diffusion cells and human cadaver skin...
July 12, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28686222/multiple-sclerosis-immunopathology-and-treatment-update
#11
REVIEW
Narges Dargahi, Maria Katsara, Theodore Tselios, Maria-Eleni Androutsou, Maximilian de Courten, John Matsoukas, Vasso Apostolopoulos
The treatment of multiple sclerosis (MS) has changed over the last 20 years. All immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a medical challenge in MS to develop a treatment for progressive forms. The most common injectable disease-modifying therapies in RRMS include β-interferons 1a or 1b and glatiramer acetate. However, one of the major challenges of injectable disease-modifying therapies has been poor treatment adherence with approximately 50% of patients discontinuing the therapy within the first year...
July 7, 2017: Brain Sciences
https://www.readbyqxmd.com/read/28653862/optimal-response-to-dimethyl-fumarate-associates-in-ms-with-a-shift-from-an-inflammatory-to-a-tolerogenic-blood-cell-profile
#12
Silvia Medina, Noelia Villarrubia, Susana Sainz de la Maza, José Lifante, Lucienne Costa-Frossard, Ernesto Roldán, Carmen Picón, José C Álvarez-Cermeño, Luisa M Villar
BACKGROUND: The precise mechanism of action of dimethyl fumarate (DMF) treatment in MS remains unknown. OBJECTIVE: To identify the changes in the blood lymphocyte profile of MS patients predicting no evidence of disease activity (NEDA) status after DMF treatment. METHODS: We studied blood lymphocyte subsets of 64 MS patients treated with DMF at baseline and after 6 months of treatment by flow cytometry. NEDA (41 patients) or ongoing disease activity (ODA, 23 patients) were monitored after a year of follow-up...
June 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28622251/treating-relapsing-multiple-sclerosis-with-dimethyl-fumarate
#13
Delilah J McCarty
No abstract text is available yet for this article.
July 15, 2017: Nurse Practitioner
https://www.readbyqxmd.com/read/28616447/natalizumab-pml-survivors-with-subsequent-ms-treatment-clinico-radiologic-outcome
#14
Elisabeth Maillart, Jean-Sebastien Vidal, David Brassat, Bruno Stankoff, Agnès Fromont, Jérôme de Sèze, Frédéric Taithe, Pierre Clavelou, Bertrand Bourre, Valérie Delvaux, Audrey Rico, Pierre Labauge, Ayman Tourbah, Christine Lebrun, Jean Pelletier, Thibault Moreau, Céline Louapre, Catherine Lubetzki, Caroline Papeix
OBJECTIVE: To describe the clinico-radiologic outcome of MS patients with natalizumab-related progressive multifocal leukoencephalopathy (Nz-PML) surviving and receiving disease-modifying therapy (DMT). METHODS: We describe clinical and radiologic evolution of Nz-PML survivors in an observational retrospective multicenter cohort to clarify the effect of different subsequent MS DMT strategies. Twenty-three patients from 11 centers were analyzed. Outcomes were (1) clinical efficacy of post-PML MS DMT, (2) radiologic efficacy of post-PML MS DMT, (3) radiologic evolution of PML lesion, and (4) disability progression...
May 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28607757/lymphocyte-subtypes-in-relapsing-remitting-multiple-sclerosis-patients-treated-with-dimethyl-fumarate
#15
C Chaves, R Ganguly, C Ceresia, A Camac
BACKGROUND: Recent data suggest that lymphopenia is more prevalent than reported in relapsing-remitting multiple sclerosis (RRMS) patients taking dimethyl fumarate (DMF). OBJECTIVE: The objective of this study was to investigate the effect of DMF on lymphocyte subtypes in RRMS patients with and without lymphopenia. METHOD: A retrospective study compared lymphocyte subtypes in DMF-treated RRMS patients with low (G1, n = 35) and normal lymphocyte counts (G2, n = 24)...
April 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/28606007/dimethyl-fumarate-improves-white-matter-function-following-severe-hypoperfusion-involvement-of-microglia-macrophages-and-inflammatory-mediators
#16
Jill H Fowler, Jamie McQueen, Philip R Holland, Yasmina Manso, Martina Marangoni, Fiona Scott, Emma Chisholm, Robert H Scannevin, Giles E Hardingham, Karen Horsburgh
The brain's white matter is highly vulnerable to reductions in cerebral blood flow via mechanisms that may involve elevated microgliosis and pro-inflammatory pathways. In the present study, the effects of severe cerebral hypoperfusion were investigated on white matter function and inflammation. Male C57Bl/6J mice underwent bilateral common carotid artery stenosis and white matter function was assessed at seven days with electrophysiology in response to evoked compound action potentials (CAPs) in the corpus callosum...
January 1, 2017: Journal of Cerebral Blood Flow and Metabolism
https://www.readbyqxmd.com/read/28602832/fumarate-decreases-edema-volume-and-improves-functional-outcome-after-experimental-stroke
#17
Bettina Hjelm Clausen, Louise Lundberg, Minna Yli-Karjanmaa, Nellie Anne Martin, Martina Svensson, Maria Zeiler Alfsen, Simon Bertram Flæng, Kristina Lyngsø, Antonio Boza-Serrano, Helle H Nielsen, Pernille B Hansen, Bente Finsen, Tomas Deierborg, Zsolt Illes, Kate Lykke Lambertsen
BACKGROUND: Oxidative stress and inflammation exacerbate tissue damage in the brain after ischemic stroke. Dimethyl-fumarate (DMF) and its metabolite monomethyl-fumarate (MMF) are known to stimulate anti-oxidant pathways and modulate inflammatory responses. Considering these dual effects of fumarates, we examined the effect of MMF treatment after ischemic stroke in mice. METHODS: Permanent middle cerebral artery occlusion (pMCAO) was performed using adult, male C57BL/6 mice...
September 2017: Experimental Neurology
https://www.readbyqxmd.com/read/28589165/effects-of-fumarates-on-inflammatory-human-astrocyte-responses-and-oligodendrocyte-differentiation
#18
Dylan A Galloway, John B Williams, Craig S Moore
OBJECTIVE: Dimethyl fumarate (DMF) is a fumaric acid ester approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). In both the brain and periphery, DMF and its metabolite monomethyl fumarate (MMF) exert anti-inflammatory and antioxidant effects. Our aim was to compare the effects of DMF and MMF on inflammatory and antioxidant pathways within astrocytes, a critical supporting glial cell in the central nervous system (CNS). Direct effects of fumarates on neural progenitor cell (NPC) differentiation toward the oligodendrocyte lineage were also assessed...
June 2017: Annals of Clinical and Translational Neurology
https://www.readbyqxmd.com/read/28576902/application-of-pharmacogenomics-to-investigate-adverse-drug-reactions-to-the-disease-modifying-treatments-for-multiple-sclerosis-a-case-control-study-protocol-for-dimethyl-fumarate-induced-lymphopenia
#19
Kaarina Kowalec, Elaine Kingwell, Robert Carruthers, Ruth Ann Marrie, Sasha Bernatsky, Anthony Traboulsee, Colin J D Ross, Bruce Carleton, Helen Tremlett
INTRODUCTION: Adverse drug reactions (ADRs) are a global public health issue. The potential for pharmacogenomic biomarkers has been demonstrated in several therapeutical areas, including HIV infection and oncology. Dimethyl fumarate (DMF) is a licensed disease-modifying therapy for the treatment of multiple sclerosis (MS). The use of DMF in MS has been associated with a severe reduction in lymphocyte counts and reports of progressive multifocal leukoencephalopathy. Here, we outline the protocol for a case-control study designed to discover genomic variants associated with DMF-induced lymphopenia...
June 2, 2017: BMJ Open
https://www.readbyqxmd.com/read/28574825/dimethyl-fumarate-reduces-the-risk-of-mycotoxins-via-improving-intestinal-barrier-and-microbiota
#20
Ning Ma, Yi Wu, Fei Xie, Kexin Du, Yuan Wang, Linxin Shi, Linbao Ji, Tianyi Liu, Xi Ma
The effects of dimethyl fumarate (DMF) on mycotoxins and animal growth performance are well documented. However, its mechanism of anti-mildew effects is still unknown. The current study investigated how DMF detoxified the mycotoxin and improved the growth performance using BALB/c mice model, especially its effects on intestinal barrier function and gut micro-ecology. Our study also compared with the ultraviolet radiation (UR) treatment, a traditional anti-mildew control (TC). The results indicated that the DMF treatment had a lower contents of mycotoxin, better growth performance and improved mucosal morphology (P < 0...
July 4, 2017: Oncotarget
keyword
keyword
53593
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"